Standard Biotools Inc. revenue by segment LAB

Annual Quarterly

Standard Biotools Inc. splits its revenue into 11 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Consumables at $36.2 million, 42% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	84	85	91	106	98	131	138	117	113	102	104
Product And Service	—	—	170 share 186.5%	—	96 share 98.2%	—	—	—	—	—	—
Assay Services	—	—	56 +7900.6% share 62.1%	1 +43.2% share 0.7%	0 share 0.5%	—	—	—	—	—	—
Consumables	38 -1.1% share 44.6%	36 -10.6% share 42.5%	41 -2.9% share 44.5%	42 share 39.3%	—	58 share 44.3%	—	45 -5.7% share 38.7%	48 +15.0% share 42.6%	42 share 41.1%	—
Services	—	—	—	—	—	26 +14.8% share 19.8%	23 +6.1% share 16.3%	21 +10.2% share 18.1%	19 +11.3% share 17.1%	17 share 17.0%	—
Instruments	24 -2.3% share 28.5%	25 +2.1% share 29.8%	25 -33.6% share 27.3%	37 share 35.2%	—	42 -6.7% share 32.5%	46 -8.9% share 33.0%	50 +9.9% share 42.6%	45 +7.0% share 40.3%	43 share 41.7%	—
Instrument Support Services	—	—	25 -2.5% share 27.1%	25 +8.9% share 23.8%	23 share 23.7%	—	—	—	—	—	—
Services And Other Revenue	23 -3.8% share 26.9%	24 -7.5% share 27.7%	26 share 28.1%	—	—	—	—	—	—	—	—
Collaboration And Other Revenue	—	—	5 +307.1% share 5.2%	1 -34.8% share 1.1%	2 share 1.8%	—	—	1 share 0.5%	—	—	—
Collaboration Revenue	—	—	—	—	—	3 -71.1% share 2.0%	9 share 6.4%	—	—	—	—
Grant	—	—	—	—	—	2 -56.0% share 1.2%	4 +553.3% share 2.6%	1 share 0.5%	—	—	—
License	—	—	—	—	—	0 -95.4% share 0.1%	3 share 2.3%	—	—	0 share 0.2%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: LAB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Boston, MA
SEC filer status: Accelerated filer
SEC CIK: 1162194
Former names: FLUIDIGM CORP (until Apr 1, 2022)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.